AstraZeneca targets $80bn revenue by 2030, driven by oncology and new drugs, but faces patent risks and tough competition.

TEM is a data-rich platform that recently clinched a $200 million deal with AstraZeneca. TEM’s main bet is now on AI for ...

Pharmaceutical giant AstraZeneca is suing Utah’s attorney general and insurance commissioner over a law passed during the ...

The AstraZeneca PLC ADR AZN rose 1.64% to $73.00 Wednesday, on what proved to be an all-around mixed trading session for the ...

EU approves AstraZeneca’s Calquence in combo with venetoclax, with or without obinutuzumab to treat adult patients with previously untreated CLL: Cambridge, UK Saturday, June 7, ...

Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at the first sign of resistance to standard ...

Drugmaker AstraZeneca has agreed to pay $50.9 million to settle a class action lawsuit in U.S. court accusing the company of ...

AstraZeneca Plc and Daiichi Sankyo Co.’s Enhertu delayed the advance of a common type of breast cancer by more than a year in ...

AstraZeneca has presented results for the SERENA-6 trial at the American Society for Medical Oncology (ASMO)'s 2025 ...

AstraZeneca PLC closed 19.58% short of its 52-week high of £133.88, which the company reached on September 3rd.

AstraZeneca CEO Pascal Soriot views the company's stock price — up just 10% year-to-date — as a marker of how he is doing. He ...

Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, ...